Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | PGK1 | P00558 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 10/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425442 | 0.92 | ALDH1A1 (0.50) | ALDH1A1CYP3A4PGK1TSHRMAPK1 | |
| SCHEMBL12658937 | 0.88 | PDK1 (0.45) | ALDH1A1CYP3A4PGK1TSHRMAPK1 | |
| SCHEMBL10979430 | 0.87 | ALDH1A1 (0.51) | ALDH1A1CYP3A4PGK1TSHRMAPK1 | |
| SCHEMBL11127500 | 0.86 | PDK1 (0.46) | ALDH1A1CYP3A4PGK1TSHRMAPK1 | |
| SCHEMBL14928472 | 0.85 | TSHR (0.42) | ALDH1A1CYP3A4PGK1TSHRMAPK1 | |
| SCHEMBL18138428 | 0.84 | TSHR (0.47) | ALDH1A1CYP3A4PGK1TSHRMAPK1 | |
| SCHEMBL305309 | 0.83 | ALDH1A1 (0.50) | ALDH1A1CYP3A4PGK1TSHRMAPK1 | |
| SCHEMBL9180125 | 0.82 | TSHR (0.62) | ALDH1A1CYP3A4PGK1TSHRMAPK1 | |
| SCHEMBL5468154 | 0.82 | TSHR (0.46) | ALDH1A1CYP3A4PGK1TSHRMAPK1 | |
| SCHEMBL17533446 | 0.81 | TSHR (0.42) | ALDH1A1CYP3A4PGK1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188083-A1 | Modulators of Histone Acetyltransferase 1 and Methods of Treatment Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2022272313-A1 | MODULATORS OF HISTONE ACETYLTRANSFERASE 1 AND METHODS OF TREATMENT THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | DAIICHI PHARMACEUTICAL CO.,LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-6251903-B1 | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist | COCENSYS, INC. | 2001-06-26 | — | — | US | disclosed |
| US-6147075-A | ANALGESICS; PSYCHOLOGICAL DISORDERS | COCENSYS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0732942-A4 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | COCENSYS INC (US) | 2000-03-22 | — | — | EP | disclosed |
| US-5977107-A | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists | COCENSYS, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5631373-A | NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0732942-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995012417-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1995-05-11 | — | — | WO | disclosed |
| US-4532350-A | Process for the selective preparation of meta-chloroanilines | RHONE-POULENC AGROCHIMIE (FR) | 1985-07-30 | — | — | US | disclosed |
| US-4418213-A | HYDRODEHALOGENATION LEWIS ACID AND NOBLE METAL CATALYSTS | RHONE-POULENC AGROCHIMIE (FR) | 1983-11-29 | — | — | US | disclosed |
| US-4351959-A | Process for preparation of anilines substituted by chlorine in the meta-position | RHONE-POULENC AGROCHIMIE (FR) | 1982-09-28 | — | — | US | disclosed |
| US-4340759-A | Process for the preparation of anilines substituted by chlorine in the meta-position | RHONE-POULENC AGROCHIMIE (FR) | 1982-07-20 | — | — | US | disclosed |
| US-4324914-A | Process for preparation of anilines substituted by chlorine in the meta-position | RHONE-POULENC AGROCHIMIE (FR) | 1982-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188083-A1 | Modulators of Histone Acetyltransferase 1 and Methods of Treatment Thereof | EP300, HDAC1, NAT1 | ALDH1A1 730/4885CYP3A4 4395/4885PGK1 915/4885 |
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | UGT1A4, VPS4B, CYP3A4 | ALDH1A1 43/4885CYP3A4 3/4885PGK1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.